Objective To observe the expression of serum mid regional peptide of precursor adrenal medullary(MR-ProADM)and ga-lactin-3(Gal-3)in patients with chronic heart failure(CHF)and analyze their clinical significance.Methods Eighty patients with CHF treated in the North Anhui Coal Power Group General Hospital from July 2020 to June 2021 were prospectatively selected as CHF group,then 80 healthy people who underwent physical examination during the same period were selected as the control group.And grouped again into NYHA ClassⅡ group(n=27),NYHA Class Ⅲ group(n=32)and NYHA Class Ⅳ group(n=21)according to NYHA classification.Patients in the CHF group were followed up for 12 months and again divided into poor prognosis group(n=26)and non-poor prognosis group(n=54)ac-cording to the occurrence of endpoint events.Serum MR-ProADM and Gal-3 levels were compared between CHF group and control group,NY-HA groups,poor prognosis group and non-poor prognosis group before and after standardized anti-heart failure treatment.The predictive value of serum MR-ProADM and Gal-3 levels on adverse prognosis of CHF patients was analyzed by receiver operating characteristic(ROC)curve.Results The levels of serum MR-ProADM and Gal-3 in the CHF group were(702.69±47.16)pmol/mL and(26.11±5.78)ng/mL,re-spectively,which were significantly higher than those in the control group[(587.21±40.69)pmol/mL and(2.34±0.69)ng/mL],the differ-ences were statistically significant(P＜0.05).In the CHF group,the serum MR-ProADM and Gal-3 levels in grade Ⅳ group were(755.93 ±62.37)pmol/mL,(36.85±7.95)ng/mL,respectively,which were significantly higher than those in grade Ⅲ group[(690.61±49.26)pmol/mL,(20.21±4.07)ng/mL]and grade Ⅱ group[(625.87±48.56)pmol/mL,(13.69±3.28)ng/mL],the differences were statisti-cally significant(P＜0.05).Serum MR-ProADM and Gal-3 levels of NYHA groups in CHF group after treatment were significantly lower than those before treatment,and the differences were statistically significant(P＜0.05).The serum levels of MR-ProADM and Gal-3 in the poor prognosis group were(711.26±47.22)pmol/mL,(29.87±5.39)ng/mL,respectively,which were significantly higher than those in the non-poor prognosis group[(639.58±45.73)pmol/mL,(15.61±3.78)ng/mL],the differences were statistically significant(P＜0.05).The area under the curve(AUC)of the combined detection of serum MR-ProADM and Gal-3 in the assessment of adverse outcomes in CHF patients was 0.893(95％CI:0.772-0.951,P＜0.001),which was higher than that predicted by serum MR-ProADM alone[0.751(95％CI:0.619-0.892,P＜0.001)],or serum Gal-3 predicted AUC[0.855(95％CI:0.751-0.935,P＜0.001)].Conclusion Serum MR-ProADM and Gal-3 can be used as biomarkers for diagnosis,risk stratification,treatment effect evaluation and prognosis prediction of CHF.
关键词
慢性心力衰竭/肾上腺髓质前体中段肽/半乳糖凝集素-3/临床意义
Key words
Chronic heart failure/Mid regional peptide of precursor adrenal medullary/Galectin-3/Clinical significance
维普
万方数据